Alpha Cognition (XCNQ:ACOG) Debt-to-Equity : -0.26 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Debt-to-Equity?

Alpha Cognition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$1.64 Mil. Alpha Cognition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Alpha Cognition's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$-6.32 Mil. Alpha Cognition's debt to equity for the quarter that ended in Dec. 2023 was -0.26.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Alpha Cognition's Debt-to-Equity or its related term are showing as below:

XCNQ:ACOG' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.92 Med: -0.07 Max: 205.9
Current: -0.26

During the past 4 years, the highest Debt-to-Equity Ratio of Alpha Cognition was 205.90. The lowest was -0.92. And the median was -0.07.

XCNQ:ACOG's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs XCNQ:ACOG: -0.26

Alpha Cognition Debt-to-Equity Historical Data

The historical data trend for Alpha Cognition's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Debt-to-Equity Chart

Alpha Cognition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

205.90

0.12

-0.92

-0.26

Alpha Cognition Quarterly Data
	Jan20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial									-0.92	0.89	-2.42	-0.19	-0.26

Competitive Comparison of Alpha Cognition's Debt-to-Equity

For the Biotechnology subindustry, Alpha Cognition's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpha Cognition's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Cognition's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Alpha Cognition's Debt-to-Equity falls into.

Alpha Cognition Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Alpha Cognition's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.637	+	0)	/	-6.323
	=	-0.26

Alpha Cognition's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.637	+	0)	/	-6.323
	=	-0.26

Alpha Cognition (XCNQ:ACOG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Alpha Cognition Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpha Cognition (XCNQ:ACOG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (XCNQ:ACOG) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ACOGF:USA

Address

301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2

Website

https://www.alphacognition.com

Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.

Alpha Cognition (XCNQ:ACOG) Headlines

No Headlines